Novartis: to donate potential coronavirus treatment
(CercleFinance.com) - Novartis has committed to donate up to 130 million doses of its generic hydroxychloroquine, a drug that is currently under evaluation in clinical trials for the treatment of COVID-19.
The Swiss drugmaker said that it is also exploring further scaling of capacity to increase supply, working with manufacturers worldwide to meet global demand.
Its Sandoz division currently holds a registration for hydroxychloroquine in the US, and will pursue appropriate regulatory authorizations from US and European regulators.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Swiss drugmaker said that it is also exploring further scaling of capacity to increase supply, working with manufacturers worldwide to meet global demand.
Its Sandoz division currently holds a registration for hydroxychloroquine in the US, and will pursue appropriate regulatory authorizations from US and European regulators.
Copyright (c) 2020 CercleFinance.com. All rights reserved.